These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 5022451)

  • 1. EEG and urinary non-catecholic amine changes during L-dopa therapy of Parkinson's disease.
    Marjerrison G; Boulton AA; Rajput AH
    Dis Nerv Syst; 1972 Mar; 33(3):164-9. PubMed ID: 5022451
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of L-dopa therapy on urinary p-tyramine excretion and EEG changes in Parkinson's disease.
    Boulton AA; Marjerrison GL
    Nature; 1972 Mar; 236(5341):76-8. PubMed ID: 4553458
    [No Abstract]   [Full Text] [Related]  

  • 3. Urinary excretion of dopamine and homovanillic acid during L-dopa treatment of Parkinson's disease.
    Streifler M; Vardi Y; Kesten M; Oberman Z; Herzberg M
    Isr J Med Sci; 1972 May; 81(5):597-601. PubMed ID: 5042950
    [No Abstract]   [Full Text] [Related]  

  • 4. Dopa therapy in parkinsonism effects on the EEG and amine metabolism.
    Marjerrison G; Boulton AA; Rajput A
    Int Z Klin Pharmakol Ther Toxikol; 1971 Feb; 4(2):263-6. PubMed ID: 5550423
    [No Abstract]   [Full Text] [Related]  

  • 5. The excretion of L-dopa metabolites at different hours of the day.
    Aguggini G; Meucci M; Reina G
    Curr Ther Res Clin Exp; 1972 Nov; 14(11):749-57. PubMed ID: 4629113
    [No Abstract]   [Full Text] [Related]  

  • 6. L-dopa in Parkinson's syndrome.
    Poskanzer DC
    N Engl J Med; 1969 Feb; 280(7):382-3. PubMed ID: 5764823
    [No Abstract]   [Full Text] [Related]  

  • 7. [Biochemistry and treatment of Parkinson's disease].
    Barbeau A
    Laval Med; 1970 Sep; 41(7):902-5. PubMed ID: 5509487
    [No Abstract]   [Full Text] [Related]  

  • 8. Responses of the urinary excretion of homovanillic acid and of 5-hydroxy-indol-acetic acid to treatment with L-dopa and amantadine.
    Molnár G; Fodor A
    Ther Hung; 1973; 21(1):35-40. PubMed ID: 4792890
    [No Abstract]   [Full Text] [Related]  

  • 9. [Dopa metabolism in relation to the therapy of Parkinson's syndrome].
    Pletscher A; Bartholini G
    Actual Pharmacol (Paris); 1971; 24():27-49. PubMed ID: 5150621
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term treatment of Parkinson's disease with levodopa.
    Campbell JB
    Neurology; 1970 Dec; 20(12):18-22. PubMed ID: 5531291
    [No Abstract]   [Full Text] [Related]  

  • 11. Aromatic amines and Parkinson's disease.
    Smith I; Kellow AH
    Nature; 1969 Mar; 221(5187):1261. PubMed ID: 5773846
    [No Abstract]   [Full Text] [Related]  

  • 12. Electroencephalographic changes occurring during L-dopa treatment.
    Herman MN; Rowan AJ; Goldensohn ES
    Trans Am Neurol Assoc; 1971; 96():252-4. PubMed ID: 5159096
    [No Abstract]   [Full Text] [Related]  

  • 13. Variation of levodopa metabolism with gastrointestinal absorption site.
    Sandler M; Ruthven CR; Goodwin BL; Hunter KR; Stern GM
    Lancet; 1974 Feb; 1(7851):238-40. PubMed ID: 4130247
    [No Abstract]   [Full Text] [Related]  

  • 14. L-dopa in Parkinson's disease. A report on 95 cases and review of the literature.
    Lewis I
    J Med Assoc State Ala; 1971 May; 40(11):709-18. PubMed ID: 5573008
    [No Abstract]   [Full Text] [Related]  

  • 15. Homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5HIAA) during L-dopa therapy of Parkinson's disease.
    van Woert MH; Bowers MB
    Neurology; 1970 Apr; 20(4):377. PubMed ID: 5534981
    [No Abstract]   [Full Text] [Related]  

  • 16. [The effect of alpha-DOPA on the dynamics of urinary excretion of DOPA, catecholamines and their metabolites in healthy subjects and in patients with parkinsonism].
    Matlina ESh; Kandel' EI; Vasil'ev VN; Iadgarov IS; Bol'shakova TD
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(2):205-9. PubMed ID: 4743269
    [No Abstract]   [Full Text] [Related]  

  • 17. [New methods for measurement of the tremor and rigidity in patients with Parkinson's disease treated with L-Dopa].
    Paci A; Freddi A; Barba C
    Riv Neurol; 1973; 43(1):15-39. PubMed ID: 4698011
    [No Abstract]   [Full Text] [Related]  

  • 18. Metabolism of L-dihydroxyphenylalanine by patients with Parkinson's disease.
    Tyce GM; Muenter MD; Owen CA
    Mayo Clin Proc; 1970 Sep; 45(9):645-56. PubMed ID: 5311767
    [No Abstract]   [Full Text] [Related]  

  • 19. Excretion of L-dopa and its metabolites in urine of Parkinson's disease patients receiving L-dopa therapy.
    Routh JI; Bannow RE; Fincham RW; Stoll JL
    Clin Chem; 1971 Sep; 17(9):867-71. PubMed ID: 5571485
    [No Abstract]   [Full Text] [Related]  

  • 20. The identity of the so-called pink spot in schizophrenia and Parkinson's disease.
    Heslinga FJ; van Tilburg W; Stam FC
    Psychiatr Neurol Neurochir; 1970; 73(3):157-64. PubMed ID: 5310324
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.